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Further Evidence for an Association of ABCR Alleles with Age-Related
Macular Degeneration
Rando Allikmets1 and the International ABCR Screening Consortium*
1Departments of Ophthalmology and Pathology, Columbia University, New York
Age-related macular degeneration (AMD) accounts for 150% of the registered visual disability among North
American and Western European populations and has been associated both with environmental factors, such as
smoking, and with genetic factors. Previously we have reported disease-associated variants in the ABCR (also called
ABCA4) gene in a subset of patients affected with this complex disorder. We have now tested our original hypothesis,
that ABCR is a dominant susceptibility locus for AMD, by screening 1,218 unrelated AMD patients of North
American and Western European origin and 1,258 comparison individuals from 15 centers in North America and
Europe for the two most frequent AMD-associated variants found in ABCR. These two sequence changes, G1961E
and D2177N, were found in one allele of ABCR in 40 patients (∼3.4%), and in 13 control subjects (∼0.95%).
Fisher’s two-sided exact test confirmed that these two variants are associated with AMD at a statistically significant
level ( ). The risk of AMD is elevated approximately threefold in D2177N carriers and approximatelyP ! .0001
fivefold in G1961E carriers. The identification of a gene that confers risk of AMD is an important step in unraveling
this complex disorder.
Age-related macular degeneration (AMD, also desig-
nated “ARMD2” [MIM 153800]) accounts for 150%
of the registered visual disability among the North Amer-
ican and Western European populations and has been
associated with both environmental and genetic factors
(Klein et al. 1992; Vingerling et al. 1995). Previously we
reported disease-associated variants in the Stargardt dis-
ease gene, ABCR (Allikmets et al. 1997b), in a subset
of patients affected with this complex disease trait (Al-
likmets et al. 1997a). Challenges (Dryja et al. 1998) to
this report have included the following: (1) controls were
not screened as intensively as were subjects with AMD,
(2) statistical corrections were not made for multiple
comparisons, and (3) the association might be due to
inadequate “racial matching”—that is, population strat-
ification. Also, one investigation could not find an as-
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sociation between ABCR alterations and AMD (Stone
et al. 1998).
We present new data on 1,218 patients with AMD
and 1,258 matched controls studied at 15 centers (7 in
the United States and 8 in Europe) to test the associations
with AMD of two of the more common AMD-associated
ABCR variants, G1961E and D2177N. Because all case
and control subjects were tested in a coded (masked)
fashion at each center and because this is an independent
confirmatory study, the design responds to objections
(1) and (2) above. Conducting the study in 15 centers
in the United States and Europe minimizes the possibility
of population stratification (selection bias). Each center
in this consortium recruited patients with AMD defined
according to published criteria (Bird et al. 1995; Age-
Related Eye Disease Study Research Group 1999), and
patients were categorized as having either dry (drusen
and retinal pigmentary epithelial abnormalities and/or
geographic atrophy) or wet (exudative or neovascular)
forms of AMD by clinicians without prior knowledge
of the molecular genetic analyses. The mean age ( SD)
of patients from all centers was years. Con-74.8 7.4
trols were matched to case subjects by race and age in
some centers, whereas general population (GP) racially
matched controls were used in other centers (table 1).
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Table 1
Association of G1961E and D2177N Alleles with AMD
CENTER POPULATION
AMD SAMPLES CONTROLS G1961E D2177N
Dry Wet Total GP AM Total AMD (D/W)
Control
(GP/AM) AMD (D/W)
Control
(GP/AM)
Boston/Salt Lake
City/Baltimore Eur. Am. 185 44 229 200 200 3 (3/0) 0 6 (6/0) 1 (0/1)
Houston Eur. Am. 55 46 101 100 100 1 (1/0) 0 1 (0/1) 0
Los Angeles Eur. Am. 53 50 103 158 158 5 (3/2) 1 (1/0) 4 (2/2) 0
Wuerzburg German 100 100 200 100 100 4 (1/3) 1 (0/1) 3 (2/1) 2 (0/2)
Nijmegen Dutch 24 59 83 168 168 1 (0/1) 0 1 (1/0) 3 (3/0)
Rotterdam/
Amsterdam Dutch 36 79 115 100 100 0 1 (0/1) 0 1 (0/1)
Naples/Milan Italian 31 61 92 120 51 171 3 (2/1) 0 0 0
Barcelona Spanish 10 26 36 34 34 0 0 1 (0/1) 0
Uppsala Swedish 20 82 102 100 100 1 (1/0) 1 (1/0) 2 (1/1) 0
London British 15 75 90 20 20 1 (0/1) 0 1 (0/1) 0
Paris French 4 63 67 107 107 0 0 2 (0/2) 1 (1/0)
Total (%) 533 685 1,218 653 605 1,258 19/1,218 (1.56) 4/1,258 (.32) 21/1,189 (1.77) 8/1,258 (.64)
P P = .0013 P = .014
OR (95% CI) 5.0 (1.6–20) 2.8 (1.2–7.4)
Both variants 40/1,189 (3.36%) 12/1,258 (.95%) P ! .0001
NOTE.—AM = age-matched; D = dry form of AMD; W = wet form of AMD; SLC = Salt Lake City; Eur. Am. = European American; OR =
odds ratio. P values were calculated from the two-sided Fisher’s exact test, and ORs were calculated from the exact conditional hypergeometric
distribution (Mehta and Patel 1995).
The mean ages of controls were years for73.4 6.6
the age-matched subset and years for the GP39.2 8.2
sample. Each age-matched control received a complete
eye examination, to exclude AMD. Eye examinations
were not performed on all GP controls, since these in-
dividuals were relatively young ( years) and,39.2 8.2
therefore, not at risk for AMD.
Genotyping of the G1961E and D2177N variants was
performed by a method of choice at each center. These
methods, all described elsewhere, included PCR-RFLP
scanning (Deng 1988), SSCP analysis (Orita et al. 1989;
Allikmets et al. 1997b), denaturing gradient gel electro-
phoresis (Myers et al. 1985), allele-specific oligonucleo-
tide hybridization (Conner et al. 1983), and amplifica-
tion refractory mutations system allele-specific PCR
hybridization (Newton et al. 1989). Positive controls for
the two variants were provided to each center, to ensure
a 100% detection rate and to eliminate false-negative
results. All positive cases were confirmed by direct se-
quencing. Data from the 15 centers were aggregated into
11 analysis units by grouping centers that collaborated
closely (table 1).
G1961E was found in 19/1,218 (1.56%) patients with
AMD compared with 4/1,258 (0.32%) control subjects
(table 1) (Fisher’s two-sided exact test [Mehta and Patel
1995]; ). For the pooled data, the odds ratio,P = .0013
calculated from the exact conditional hypergeometric
distribution (Mehta and Patel 1995), is 5.0 (95% con-
fidence interval [CI] 1.6–20]). An exact conditional anal-
ysis stratified on analysis unit yielded an odds ratio of
5.2 (95% CI 1.7–22). No statistically significant evi-
dence of heterogeneity of odds ratios exists among anal-
ysis units, and the prevalence is higher in the AMD group
in six of the eight units with at least one G1961E allele.
D2177N was present in 21/1,189 (1.77%) AMD
cases, compared with 8/1,258 (0.64%) controls (P =
). The pooled odds ratio, 2.8 (95% CI 1.2–7.4) was.014
similar to the odds ratio estimated by stratification on
each unit, 2.6 (95% CI 1.1–7.0). There was no statis-
tically significant evidence of heterogeneity of odds ra-
tios among units, and the prevalence of D2177N was
higher in AMD cases in 8 of the 10 units with at least
one D2177N allele.
The combination of either G1961E or D2177N was
found in 40/1,189 (3.36%) patients with AMD, com-
pared with 12/1,258 (0.95%) control subjects (P !
). The study design was directed toward increasing.0001
the power of statistical analysis by increasing the sample
size substantially with the pooling of data from all study
centers. However, if analyzed separately or in small sub-
sets, the data from almost all study centers do not show
statistical significance. This outcome is not surprising
when one views the observed low allele frequency of these
two variants. For example, analysis of the data previously
reported by Stone et al. (1998) for these two variants (3/
182 in patients, 0/96 in control subjects) by itself suggests
no association. However, in the context of the current
study, these data (1) correlate perfectly with the results
from all study centers, and (2) if included, increase the
statistical significance of the association.
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We have reported elsewhere that ABCR variants are
more prevalent among subjects manifesting the dry (non-
neovascular) form of the disease (Allikmets et al. 1997a).
Distinction between the dry and wet phenotypes is not
unambiguous (Stone et al. 1998). Whether or not these
two clinical manifestations have different genetic risk
factors remains to be elucidated. Occasionally, individ-
uals with the dry form in one eye may develop choroidal
neovascularization later in life in either the same or the
other eye (Sunness et al. 1999). Each participating cli-
nician in this consortium segregated its patient popu-
lation by phenotype, between those with the dry form,
characterized by drusen, retinal pigment epithelium
(RPE) pigmentary abnormalities, and/or geographic at-
rophy; and those manifesting the wet, or exudative (neo-
vascular), stage (Bird et al. 1995; Age-Related Eye Dis-
ease Study Research Group 1999). For the purposes of
these analyses, when different phenotypes appeared in
the two eyes, the assignment of the disease status was
based on the more severely affected eye.
Of the 1,218 patients analyzed, 533 had the dry phe-
notype and 685 had the exudative form (table 1). The
proportion of patients diagnosed with the exudative
complication was higher in European centers than in
North American centers (table 1). Together, the G1961E
and D2177N variants were present in 23/533 patients
with nonexudative disease and in 17/685 with exudative
lesions. The difference is marginally significant (P =
) with the one-sided Fisher’s exact test (Mehta and.027
Patel 1995). The pooled odds ratio was 1.77 (95% CI
0.9–3.4). Although we have demonstrated that variants
in ABCR may be associated predominantly with nonex-
udative AMD, the clinical relevance of this finding re-
mains to be determined. Future studies, with larger num-
bers of affected individuals and control subjects, may be
able to link allelic variants in ABCR to specific disease
phenotypes.
The results remain statistically significant when the
data are stratified by the type of control—age-matched
or GP. The combination of either variant occurs in 24/
863 (2.8%) cases and in 6/605 (0.99%) age-matched
controls, a statistically significant difference (P = .008
with one-sided Fisher’s exact test). Of interest, the as-
sociation is stronger with GP controls—16/355 (4.5%)
in patients, 6/653 (0.92%) in control subjects (P =
). This could be explained, however, with a rela-.0003
tively small patient sample size (355) applicable for the
analysis with the GP controls. Furthermore, we cannot
exclude that some of the heterozygous GP control sub-
jects could develop AMD later in life, since their mean
age is well below 60 years.
For population stratification to explain the above as-
sociations at any one study center, ethnic (sub)groups in
that center should both associate strongly with AMD
prevalence and segregate concordantly with the preva-
lences of both G1961E and D2177N. We know no data
that suggest substantial variation of AMD prevalence
across ethnic subgroups within the white population;
indeed, the Chesapeake Bay Watermen Study and the
Beaver Dam Eye Study in the United States and the Rot-
terdam Eye Study yield similar age-specific prevalences
of AMD (see fig. 1 in Vingerling et al. 1995). Moreover,
the direction of the association is the same in European
centers, within which populations are relatively homo-
geneous, as in US centers, within which ethnic diversity
is greater. Although the US data yield larger estimated
odds ratios than do the European data, formal tests for
differences between these odds ratios are not statistically
significant. It also seems unlikely that similar ethnic cor-
relations should occur with G1961E and D2177N,
which we have yet to find together in the same subject.
Finally, even if population stratification accounted for
an association in one analysis unit, it is difficult to imag-
ine that it could possibly account for associations in so
many diverse, geographically distributed populations
(table 1).
Other lines of evidence suggest a possible role for
ABCR in AMD. Several reports have indicated a higher
rate of AMD in parents and grandparents of patients
with recessive Stargardt disease harboring ABCR vari-
ants (Rozet et al. 1998; Lewis et al. 1999; Shroyer et al.
1999; Souied et al. 1999). Data from photoaffinity la-
beling and ATPase activity experiments (H. Sun, P. M.
Smallwood, and J. Nathans, personal communication)
indicate that both variants affect the protein function in
vitro. The mutant G1961E protein, produced after the
transfection of human embryonic kidney (293) cells with
cloned cDNA, exhibits several-fold lower binding of 8-
azido-ATP and inhibition of ATPase activity by retinal,
as compared with the wild-type ABCR protein. The
D2177N variant had no effect on 8-azido-ATP binding
but exhibited a reproducible elevation in ATPase activity
relative to the wild type (H. Sun, P. M. Smallwood, and
J. Nathans, personal communication). The physiological
consequences of the latter observation have to be further
elucidated. Functional studies of ABCR have implicated
all-trans retinal or its conjugates with phosphatidyl-
ethanolamine (PE), N-retinylidene-PE, and N-retinyl-
idene-N-retinylethanolamine (A2E), as potential sub-
strates for this transporter protein (Sun et al. 1999; Weng
et al. 1999). Mice homozygous for a null mutation in
ABCR accumulate high levels of a major fluorophore of
lipofuscin, A2E, in the RPE, a phenotype associated with
AMD in humans (Weng et al. 1999). Most recently, A2E
accumulation was also demonstrated in the RPE of
Abcr/ heterozygote mice, but at a slower, age-related
rate (Mata et al. 2000). The distinct AMD-resembling
phenotype in Abcr/ mice suggests that humans het-
erozygous for ABCR mutations may be predisposed to
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A2E accumulation and concomitant retinal or macular
disease (Mata et al. 2000).
In summary, new data from 15 centers in the United
States and Europe independently confirm the association
of ABCR alleles G1961E and D2177N with AMD.
Studying diverse populations minimizes the chance that
the associations are due to population stratification.
That similar masked assays were performed on both case
and control subjects and that the new confirmatory data
achieved statistical significance should allay earlier con-
cerns about unequal thoroughness of assays and multiple
comparisons (Dryja et al. 1998). We welcome other stud-
ies, such as sib-based transmission/disequilibrium tests,
to test against the possibility of population stratification,
but such designs have their own weaknesses and would
require much larger populations and more-difficult sam-
ple collection than did the present case-control study
(Schaid and Rowland 1998). Our experience indicates
that successful association analysis can be accomplished
by formation of large international consortia with care-
fully planned and unified protocols.
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